CBLLCeriBell, Inc.
The Read
CBLL’s stock fell sharply on Q4 2025 earnings due to liquidity concerns despite revenue beats, then rallied after a dilutive equity raise eased cash worries but stalled again post-Q1 2026 as in-line results offered no new growth clarity.
The schedule
- Thu15Oct
With less than three quarters of operational cash remaining, an equity financing or convertible debt issuance is projected to replenish the balance sheet.
- Mon11Jan
Strategic presentations at major January healthcare conferences will outline 2027 product launches and neurological pipeline expansions.
- Wed27Jan
Third-quarter results will redirect the market's focus to CeriBell's top-line execution and product adoption rates in neuro-diagnostics.
- Tue9Feb
The Q4 print and initial full-year 2027 guidance will establish expectations for profitability timelines and forward revenue deceleration or acceleration.
- Mon10May
First-quarter results will measure the early uptake of CeriBell's commercial initiatives and the effectiveness of late 2026 strategic resets.
Past
- Tue4Aug
Actual outcome: Bull · $22.91 at outcome
CeriBell reported robust Q2 results highlighted by 33% revenue growth and subsequently raised its full-year revenue outlook, overshadowing any concerns regarding cash burn. The stock rallied past the bull target, further fueled by FDA clearance for new AI algorithm enhancements and the securing of a CMS New Technology Add-On Payment (NTAP) ahead of its delirium monitor system launch.
CeriBell's Q2 earnings report will be closely evaluated for operating leverage and remaining cash runway, as recent high cash burn eclipses robust top-line growth.
- Mon11May
Actual outcome: Bear · $16.30 at outcome
CeriBell reported strong Q1 top-line results with 29% revenue growth, record new hospital additions, and a raised full-year outlook. However, the company posted a wider-than-expected quarterly loss of $0.52 per share compared to the consensus estimate of a $0.39 loss. The market focused heavily on these profitability concerns and widening losses, driving the stock down 18.7% and well below the bear floor.
- Sun15Mar
Actual outcome: Bull · $19.55 at outcome
CeriBell's equity financing successfully addressed liquidity needs to fund its 2026 growth initiatives, but the dilutive nature of the raise offset the positive momentum from its 25-29% revenue guidance and expansion into pediatric markets. While the company's fireside chats at TD Cowen and Raymond James highlighted strong
- Tue24Feb
Actual outcome: Bear · $18.16 at outcome
While CeriBell reported a revenue beat and met EPS estimates for Q4, the stock fell below the bear floor as investors focused on the company's precarious liquidity position and high quarterly burn rate. The persistent net loss and the looming requirement for dilutive financing overshadowed the top-line growth, validating market concerns regarding the company's limited cash runway.